Work

Modular Antigen‐Specific T‐cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins

Year: 2018

Type: article

Abstract: An artificial cell‐signaling pathway is developed that capitalizes on the T‐cell's innate extravasation ability and transforms it into a vector ( T‐cell Biofactory ) for synthesizing calibrated amounts of engineered proteins in vivo. The modularity of this pathway enables reprogramming of the T‐cell Biofactory to target biomarkers on different disease cells, e.g. cancer, viral infections, autoimmune disorders. It can be expected that the T‐cell Biofactory leads to a “living drug” that extravasates to the disease sites, assesses the disease burden, synthesizes the calibrated amount of engineered therapeutic proteins upon stimulation by the diseased cells, and reduces targeting of normal cells.

Source: Advanced Biosystems

DOI: 10.1002/adbi.201800210

Authors: Claire E. Repellin, Puja Patel, Lucia Beviglia, Harold Javitz, Lidia Sambucetti, Parijat Bhatnagar

Institutions: SRI International, Stanford Cancer Institute, Stanford University

Language: English

Topic: Cancer Research and Treatments

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering